Oxford Immunotec Global PLC (OXFD) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN cut its stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 55.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,485 shares of the company’s stock after selling 36,452 shares during the period. Wells Fargo & Company MN owned approximately 0.13% of Oxford Immunotec Global PLC worth $496,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of OXFD. American International Group Inc. increased its holdings in Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after buying an additional 904 shares in the last quarter. Parkwood LLC increased its holdings in Oxford Immunotec Global PLC by 12.9% in the second quarter. Parkwood LLC now owns 12,799 shares of the company’s stock valued at $215,000 after buying an additional 1,465 shares in the last quarter. Rhumbline Advisers increased its holdings in Oxford Immunotec Global PLC by 9.1% in the second quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock valued at $412,000 after buying an additional 2,053 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Oxford Immunotec Global PLC by 175.0% in the first quarter. Goldman Sachs Group Inc. now owns 35,678 shares of the company’s stock valued at $553,000 after buying an additional 22,704 shares in the last quarter. Finally, Teachers Advisors LLC increased its holdings in Oxford Immunotec Global PLC by 15.7% in the first quarter. Teachers Advisors LLC now owns 46,200 shares of the company’s stock valued at $716,000 after buying an additional 6,268 shares in the last quarter. 78.79% of the stock is owned by institutional investors.

Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at $12.94 on Monday. Oxford Immunotec Global PLC has a 1-year low of $12.19 and a 1-year high of $19.51. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38.

Several analysts have recently commented on OXFD shares. Zacks Investment Research lowered shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, August 30th. BTIG Research set a $21.00 price target on shares of Oxford Immunotec Global PLC and gave the company a “buy” rating in a research report on Tuesday, October 31st. Cowen and Company reiterated a “buy” rating and issued a $19.00 price target on shares of Oxford Immunotec Global PLC in a research report on Thursday, September 28th. Robert W. Baird reiterated a “buy” rating and issued a $20.00 price target on shares of Oxford Immunotec Global PLC in a research report on Wednesday, November 1st. Finally, ValuEngine lowered shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Three investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $19.75.

In other Oxford Immunotec Global PLC news, CEO Peter Wrighton-Smith sold 55,000 shares of Oxford Immunotec Global PLC stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total value of $922,900.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Peter Edwardson sold 9,739 shares of Oxford Immunotec Global PLC stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $16.14, for a total transaction of $157,187.46. Following the completion of the transaction, the chief operating officer now owns 92,905 shares in the company, valued at approximately $1,499,486.70. The disclosure for this sale can be found here. In the last quarter, insiders sold 70,739 shares of company stock worth $1,167,597. 8.11% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Oxford Immunotec Global PLC (OXFD) Shares Sold by Wells Fargo & Company MN” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/11/13/oxford-immunotec-global-plc-oxfd-shares-sold-by-wells-fargo-company-mn.html.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply